Ellis Investment Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $226K | Sell |
3,923
-760
| -16% | -$43.6K | 0.03% | 265 |
|
|
2026
Q1 | $284K | Buy |
4,683
+896
| +24% | +$52.2K | 0.05% | 218 |
|
|
2025
Q4 | $204K | Buy |
+3,787
| New | +$182K | 0.04% | 247 |
|
|
2025
Q3 | – | Sell |
-4,321
| Closed | -$200K | – | 238 |
|
|
2025
Q2 | $200K | Sell |
4,321
-919
| -18% | -$45.1K | 0.04% | 236 |
|
|
2025
Q1 | $320K | Buy |
5,240
+54
| +1% | +$3.15K | 0.07% | 176 |
|
|
2024
Q4 | $293K | Buy |
5,186
+848
| +20% | +$47.4K | 0.06% | 185 |
|
|
2024
Q3 | $224K | Buy |
+4,338
| New | +$203K | 0.04% | 217 |
|
|
2024
Q2 | – | Sell |
-6,973
| Closed | -$378K | – | 230 |
|
|
2024
Q1 | $378K | Sell |
6,973
-845
| -11% | -$43K | 0.08% | 161 |
|
|
2023
Q4 | $401K | Buy |
7,818
+144
| +2% | +$7.56K | 0.09% | 148 |
|
|
2023
Q3 | $445K | Buy |
7,674
+137
| +2% | +$8.39K | 0.11% | 139 |
|
|
2023
Q2 | $482K | Buy |
7,537
+548
| +8% | +$36.7K | 0.12% | 138 |
|
|
2023
Q1 | $484K | Sell |
6,989
-181
| -3% | -$12.8K | 0.13% | 139 |
|
|
2022
Q4 | $516K | Buy |
7,170
+26
| +0.4% | +$1.96K | 0.14% | 127 |
|
|
2022
Q3 | $507K | Sell |
7,144
-510
| -7% | -$37K | 0.14% | 124 |
|
|
2022
Q2 | $589K | Sell |
7,654
-253
| -3% | -$19.3K | 0.16% | 115 |
|
|
2022
Q1 | $577K | Sell |
7,907
-1,969
| -20% | -$132K | 0.14% | 127 |
|
|
2021
Q4 | $615K | Buy |
9,876
+246
| +3% | +$14.4K | 0.14% | 123 |
|
|
2021
Q3 | $569K | Buy |
9,630
+1
| +0% | +$66 | 0.14% | 119 |
|
|
2021
Q2 | $643K | Buy |
9,629
+617
| +7% | +$40.2K | 0.16% | 103 |
|
|
2021
Q1 | $569K | Buy |
9,012
+41
| +0.5% | +$2.55K | 0.16% | 112 |
|
|
2020
Q4 | $556K | Sell |
8,971
-36
| -0.4% | -$2.21K | 0.17% | 104 |
|
|
2020
Q3 | $543K | Sell |
9,007
-10
| -0.1% | -$602 | 0.19% | 91 |
|
|
2020
Q2 | $535K | Buy |
9,017
+38
| +0.4% | +$2.27K | 0.2% | 90 |
|
|
2020
Q1 | $492K | Sell |
8,979
-1,463
| -14% | -$89.4K | 0.23% | 74 |
|
|
2019
Q4 | $661K | Buy |
10,442
+605
| +6% | +$34.6K | 0.22% | 83 |
|
|
2019
Q3 | $498K | Buy |
9,837
+56
| +0.6% | +$2.63K | 0.18% | 96 |
|
|
2019
Q2 | $451K | Buy |
9,781
+1,612
| +20% | +$75.1K | 0.17% | 96 |
|
|
2019
Q1 | $384K | Buy |
8,169
+2,892
| +55% | +$144K | 0.16% | 107 |
|
|
2018
Q4 | $274K | Buy |
+5,277
| New | +$284K | 0.13% | 123 |
|
Other funds holding BMY
Ellis Investment Partners's BMY Position: Q2 2026 in Review
Ellis Investment Partners reduced its Bristol-Myers Squibb (BMY) stake by 16% in Q2 2026, selling an estimated $43.6K and leaving 3,923 shares worth $226K. The position accounts for 0.03% of the portfolio, ranked #265.
Ellis Investment Partners first reported a position in BMY in Q4 2018 and has held it in 29 quarters since. The position peaked at $661K in Q4 2019. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Ellis Investment Partners held 3,923 shares of Bristol-Myers Squibb worth $226K as of Q2 2026.
- Ellis Investment Partners sold 760 Bristol-Myers Squibb shares in Q2 2026, an estimated $43.6K.
- Bristol-Myers Squibb made up 0.03% of Ellis Investment Partners's portfolio in Q2 2026, its #265 holding.
- Ellis Investment Partners first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 29 quarters since.
- Ellis Investment Partners's Bristol-Myers Squibb position peaked at $661K in Q4 2019.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Ellis Investment Partners's 13F filing for Q2 2026, filed 5 Aug 2026.